Over two million people in Europe live with an inflammatory bowel disease (IBD), and the number of patients is increasing. Currently, the available therapies show low efficacy and side effects. Therefore, the New Deal project aims to find a selective and local therapy to treat this prevalent disease.

We are developing an ambitious therapeutic strategy, and that requires many different steps that involve intensive scientific research but also fine technical work. The New Deal approach combines the therapeutic potential of molecules called siRNAs and the versatility of nanotechnology. However, understanding the science behind this process may turn out difficult for people out of scientific world.

To shed light in how our project is executed we have prepared this video. In the first part of the video we explain the basics of the central dogma of molecular biology: how our genetic information is stored as DNA, how it is organized and, most importantly, how it is expressed, as this is the basis of our therapeutic strategy. We give insight about the natural RNA interference process and the molecules that carry it out in the New Deal project: siRNAs. We show also how siRNAs could tackle the inflammation found in the intestine of IBD patients.

The second part of the video focuses on the other innovation of the New Deal project: the drug delivery. siRNAs have to arrive to the intestinal cells in order to make their effect, and our strategy uses nanoparticles to bring these molecules to their destination unharmed. We show how these nanocarriers work and how they are produced.

From the first experiment to the last one, the New Deal project partners are working hard to develop an efficient treatment for IBD. You will get to see some of the scientific work they do first-hand, as our partners from the Atomic Energy and Alternative Energies Commission in Grenoble (France) have kindly opened the doors of their laboratories!  We hope you enjoy our video!